Gut microbiome linked to hypoglycemia in new study
NCT ID NCT03385707
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at 28 people who experience low blood sugar (hypoglycemia) after eating, often due to past stomach surgery. Researchers want to see if the types of bacteria in the gut are linked to how often and how severely blood sugar drops. Participants wear a continuous glucose monitor and provide stool samples to analyze their microbiome.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward new ways to manage or predict hypoglycemia by understanding gut bacteria.
- What could go wrong
- This is a small, observational study with only 28 participants, so results may not apply widely. It looks for correlations, not treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 28 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2019
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who experience hypoglycemia after bariatric or other upper gastrointestinal surgery or those with reactive hypoglycemia in the absence of surgery.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Males or females diagnosed with ongoing post-bariatric, post-gastric surgery or other forms of postprandial hypoglycemia with prior episodes of neuroglycopenia 2. Age 18-65 years of age, inclusive, at screening. 3. Willingness to provide informed consent and follow all study procedures, including attending all scheduled visits. Exclusion Criteria 1. Documented hypoglycemia occurring in the fasting state (\> 12 hours fast); 2. Chronic kidney disease stage 4 or 5 (including end-stage renal disease); 3. Hepatic disease, including serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin \< 3.0 g/dL; or serum bilirubin \> 2.0; 4. Congestive heart failure, New York Heart Association (NYHA) class II, III or IV; 5. History of myocardial infarction, unstable angina or revascularization within the past 6 months or 2 or more risk factors for coronary artery disease including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use. 6. History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia 7. Concurrent administration of β-blocker therapy; 8. History of a cerebrovascular accident; 9. Seizure disorder (other than with suspect or documented hypoglycemia); 10. Active treatment with any diabetes medications except for acarbose; 11. Active treatment with octreotide or diazoxide; 12. Active malignancy, except basal cell or squamous cell skin cancers; 13. Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease); 14. Known insulinoma; 15. Major surgical operation within 30 days prior to screening; 16. Hematocrit \< 33%; 17. Bleeding disorder, treatment with warfarin, or platelet count \<50,000; 18. Blood donation (1 pint of whole blood) within the past 2 months; 19. Active alcohol abuse or substance abuse; 20. Current administration of oral or parenteral corticosteroids; 21. Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. 22. Use of an investigational drug within 30 days prior to screening.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypoglycemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Joslin Diabetes Center
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain scans may predict who is most at risk for dangerous low blood sugar
- Mapping the hormone behind Post-Surgery blood sugar crashes
- Can hidden heart rhythms explain dialysis risks?
- Could a glucose monitor and education shield seniors from Insulin's dangerous side?
- Hidden sensor reveals dangerous blood sugar dips during routine eye surgery
- Could a simple sugar help people with type 1 diabetes exercise safely?